IP Library Granted Patent US 12,564,677
Granted Patent B2
US 12,564,677 · App. 17/075,423 · Granted Mar 3, 2026

Systems and methods for automated insulin delivery response to inaccurate or missed glucose values

Inventors: Jacob Kearns (San Diego, CA); Michael Michaud (San Diego, CA); Geoffrey A. Kruse (San Diego, CA); Garrett Marin (San Diego, CA); Paul Harris (San Diego, CA); Thomas R. Ulrich (Oceanside, CA); Brendan Nichols (San Diego, CA)
Assignee: Tandem Diabetes Care, Inc.
A61M5/1723A61M5/142A61M2205/18A61M2205/3331A61M2205/3368A61M2205/3584A61M2205/42A61M2205/505A61M2205/52A61M2209/01A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,564,677
App. No.
17/075,423
Granted
Mar 3, 2026
Kind
B2
Abstract

Disclosed herein are systems and methods incorporating an ambulatory infusion pump and a CGM. These systems that can include software and related methods to provide improved automated insulin delivery algorithms that enable the algorithms to safely continue delivering insulin for some time periods of missing or known inaccurate glucose values.

Claims (38)

1 . A system, comprising:

a pump mechanism configured to facilitate delivery of insulin to a user;

a user interface;

a communication element adapted to receive glucose levels from a continuous glucose monitor; and

a processor functionally linked to the pump mechanism, the user interface, and the communication element, wherein the processor is configured to:

automatically calculate insulin doses with a closed-loop delivery algorithm based on glucose levels received from the continuous glucose monitor;

automatically deliver the insulin doses calculated by the closed-loop delivery algorithm to the user with the pump mechanism;

determine that glucose levels are not being received from the continuous glucose monitor;

while the glucose levels are not being received, enable the closed-loop delivery algorithm to continue to automatically calculate insulin doses for automatic delivery with the pump mechanism for a predetermined period of time based on execution of a safety mechanism associated with the closed-loop delivery algorithm, wherein the safety mechanism (i) determines a current glucose value noise based on recent glucose levels received from the continuous glucose monitor and a variance between the glucose levels and predicted glucose levels and (ii) reduces an amount of one or more insulin doses or delays delivery of one or more insulin doses if the current glucose value noise is above a threshold; and

terminate the automatic delivery to the user with the pump mechanism in accordance with a determination that the glucose levels have not been received for a time longer than the predetermined period of time.

2 . The system of claim 1 , wherein the safety mechanism is a glucose value noise filter.

3 . The system of claim 2 , wherein the glucose value noise filter is based on one or more of an age of the user, a total daily insulin of the user, a weight predicted insulin action time for the user, and a weight predicted insulin response time for the user.

4 . The system of claim 2 , wherein the glucose value noise filter is configured to reduce an amount of one or more insulin doses or delay delivery of one or more insulin doses if an amount of noise exceeds a threshold.

5 . The system of claim 1 , wherein the safety mechanism determines glucose value noise based on a variance between glucose levels.

6 . The system of claim 1 , wherein the safety mechanism sets a maximum increase in an insulin delivery rate that can be delivered based on the closed-loop delivery algorithm.

7 . The system of claim 1 , wherein the safety mechanism lowers an aggressiveness of the closed-loop delivery algorithm by reducing automatic correction boluses and increases to basal delivery calculated by the closed-loop delivery algorithm.

8 . The system of claim 7 , wherein the safety mechanism lowers the aggressiveness of the closed-loop delivery algorithm if the glucose levels were below a low threshold when it was determined that the glucose levels were not being received or that the glucose levels were likely inaccurate.

9 . The system of claim 1 , wherein the safety mechanism estimates known inaccurate or missing glucose values based on previous or subsequent accurate glucose values.

10 . The system of claim 9 , wherein the safety mechanism estimates known inaccurate or missing glucose values using linear regression.

11 . The system of claim 9 , wherein the safety mechanism uses a most recent accurate glucose value in place of known inaccurate or missing glucose values.

12 . The system of claim 9 , wherein the safety mechanism uses a next subsequent accurate glucose value in place of known inaccurate or missing glucose values.

13 . The system of claim 1 , wherein the safety mechanism gives less weight to known inaccurate glucose values when calculating insulin doses.

14 . The system of claim 1 , wherein the safety mechanism is configured to discard known inaccurate glucose levels.

15 . The system of claim 14 , wherein the safety mechanism is configured to replace discarded known inaccurate glucose values with accurate glucose values.

16 . The system of claim 1 , wherein the safety mechanism is configured to use past glucose values along with a physiological model to continue automatically delivering insulin doses.

17 . The system of claim 1 , wherein the safety mechanism is configured to reduce an amount of one or more insulin doses or delay delivery of one or more insulin doses.

18 . The system of claim 17 , wherein the safety mechanism is configured to review any delayed insulin doses for subsequent delivery upon receiving accurate glucose values.

19 . The system of claim 1 , wherein the pump mechanism and the processor are disposed within a housing of an ambulatory infusion pump.

20 . The system of claim 1 , further comprising:

a remote control device for remotely controlling an ambulatory infusion pump including the pump mechanism;

wherein the processor is disposed within the remote control device.

21 . A method for delivering insulin, comprising:

receiving glucose levels from a continuous glucose monitor,

automatically calculating insulin doses with a closed-loop delivery algorithm based on the glucose levels received from the continuous glucose monitor;

automatically delivering the insulin doses calculated by the closed-loop delivery algorithm to a user;

determining that glucose levels are not being received from the continuous glucose monitor;

while the glucose levels are not being received, enabling the closed-loop delivery algorithm to continue to automatically calculate insulin doses for automatic delivery for a predetermined period of time based on execution of a safety mechanism associated with the closed-loop delivery algorithm, wherein the safety mechanism (i) determines a current glucose value noise based on recent glucose levels received from the continuous glucose monitor and a variance between the glucose levels and predicted glucose levels and (ii) reduces an amount of one or more insulin doses or delays delivery of one or more insulin doses if the current glucose value noise is above a threshold; and

terminating the automatic delivery to the user in accordance with a determination that the glucose levels have not been received for a time longer than the predetermined period of time.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Mar 24, 2024
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: TANDEM DIABETES CARE, INC.
Reel/Frame 066880/0918 →
SECURITY INTEREST Recorded May 25, 2022
From: TANDEM DIABETES CARE, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060179/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2020
From: KEARNS, JACOB; MICHAUD, MICHAEL; KRUSE, GEOFFREY A.; MARIN, GARRETT; HARRIS, PAUL; ULRICH, THOMAS R.; NICHOLS, BRENDAN
To: TANDEM DIABETES CARE, INC.
Reel/Frame 054178/0151 →